ALTERITY THERAPEUTICS LTD (PRNAF)
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Alterity Therapeutics Limited
- 0.0%
- 1.7K
- 999.99
Float 92.43M · FMP free float
The cost to borrow PRNAF shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- 100.0%
- No fails on record for 16–31 Oct 2026.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Sep 30, 2026 | 1.7K sh |
| Sep 15, 2026 | 2.7K sh |
| Aug 31, 2026 | 2.7K sh |
| Aug 14, 2026 | 1.0K sh |
| Jul 31, 2026 | 3.2K sh |
A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Latest sessions
| Date | Reported short |
|---|---|
| Nov 3, 2026 | 100.0% |
| Aug 26, 2026 | 100.0% |
| Jul 27, 2026 | 79.1% |
| Jul 22, 2026 | 100.0% |
| Jul 21, 2026 | 100.0% |
130 calendar days requested; 6 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.
Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
FINRA's weekly alternative trading system (dark pool) volume for PRNAF: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Sep 30, 2026 FINRA settlement, 1,694 PRNAF shares were sold short (<0.01% of a 92.43M-share float, 999.99 days to cover).